Abstract:Background: Nowadays, the number of patients with non-valvular atrial fibrillation (NVAF) complicated by end-stage renal disease (ESKD) is increasing. There are significant challenges in anticoagulation with prescription drugs because of the high risk of bleeding and embolism among these patients. However, no randomized controlled trials (RCTs) of warfarin in combination with any non-vitamin K oral anticoagulant (NOACs) have been performed in patients with baseline creatinine clearance (CrCl) <25 ml/min, which makes it difficult to justify the use of anticoagulants in such patients. Then, we aimed to collect and summarize all evidence to enable the anticoagulation of rivaroxaban, which is less cleared by the kidneys, in patients with severe renal insufficiency and to complement and improve the evidence on the use of rivaroxaban for anticoagulation. Methods: The present systematic review and meta-analysis searched the databases of PubMed , Embase , the Cochrane Library , CNKI , CBM , and Google Scholar for relevant studies from inception to 1 June 2022, with the restriction of English and Chinese. Eligible cohort studies and RCTs that reported efficacy outcomes [composite of stroke and systemic embolism (SSE), ischemic stroke (ICS), and systemic embolization] or safety outcomes [major bleeding, intracranial hemorrhage (ICH), and gastrointestinal bleeding (GIB)] of rivaroxaban in NVAF patients with ESKD were enrolled. Two authors completed the data extraction and quality assessment work, respectively. The Cochrane Collaboration tool for assessing the risk of bias was used for RCTs, and the NEW-Castle Ottawa scale was used for study quality assessment for cohort studies. Dichotomous variables were calculated as risk factors with 95% confidence intervals (CIs), and meta-analysis was performed to probe the effect of research design, rivaroxaban dose, and controlled drug factors on outcomes. Results: In total, three studies were included for meta-analysis, involving 6,071 NVAF patients with ESKD, and two studies were included for qualitative analysis. All included studies were at low risk of bias. A meta-analysis demonstrated that mix-dose rivaroxaban caused no statistical discrepancy in the occurrence of thrombotic and bleeding events when compared to the control group (embolism, LogOR: −0.64, 95% CI: −1.05 to −0.23, P:0.25; bleeding, LogOR: −0.33, 95% CI: −0.63 to −0.03, P:0.15), and low-dose rivaroxaban produced similar results (embolism, LogOR: −1.04, 95% CI: −2.15 to 0.07, P:0.61; bleeding, LogOR: −0.81, 95% CI: −1.19 to −0.44, P:0.93). Conclusion: In this study, low-dose rivaroxaban (10 mg, once a day) may benefit more than warfarin in patients with NVAF and ESKD. Systematic review registration: https://www.crd.york.ac.uk/prospero/#recordDetails, identifier CRD42022330973.

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations

Direct Factor Xa Inhibitors (rivaroxaban and Apixaban) Versus Enoxaparin for the Prevention of Venous Thromboembolism after Total Knee Replacement: A Meta-Analysis of 6 Randomized Clinical Trials

Direct Oral Anticoagulants in Patients With ESRD and Kidney Transplantation

Application of rivaroxaban in patients with non-valvular atrial fibrillation and end-stage kidney disease: A systematic review and meta-analysis

Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban

Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes

Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection

Clinical efficacy and drug safety of rivaroxaban in the prevention and treatment of senile thromboembolic diseases

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment

Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia

Abstract 13474: Rivaroxaban Reduces Major Cardiovascular and Limb Events in Patients With the High-risk Triad of Chronic Kidney Disease, Peripheral Artery Disease and Recent Lower Extremity Revascularization: Insights From VOYAGER PAD

Rivaroxaban or warfarin in atrial fibrillation and coronary stent implantation in real-world patients involving chronic kidney disease (REWRAPS): 5-year follow-up study

Anticoagulant for treatment and prophylaxis of venous thromboembolism patients with renal dysfunction: A systematic review and network meta-analysis

Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review

Meta-analysis of Efficacy and Safety of Rivaroxaban for Treatment of Deep Venous Thrombosis

Comparison of Rivaroxaban Mono-Therapy and Standard-Therapy Adjusted by CYP2C9 and VKORC1 Genotypes in Symptomatic Pulmonary Embolism.

Rivaroxaban for Thromboembolism Prophylaxis in Patients with Nephrotic Syndrome: A Single-Arm, Prospective Study

Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness

Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease

Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study

Blutungsrisiko und Blutungsnotfälle unter Rivaroxaban